Takeda completes API manufacturing facility
New facility to speed up commercialisation of new candidate drug substances
Takeda Pharmaceutical Company has completed the construction of its new API manufacturing facility for investigational antibodies that was started in March 2010.
The total construction cost is put at ¥5.5bn, and the total floor area is approximately 4,400m2.
Constructed within the premise of the Hikari plant, located in Hikari City, Yamaguchi Prefecture in Japan, this is Takeda's first manufacturing facility specialised in antibody drugs. Its aims are the research and development of manufacturing processes with high efficiency and cost competitiveness, and the production of investigational new drug substances.
Takeda has established a system aimed at facilitating rapid commercialisation of new drug candidate substances for antibody in close collaboration with Takeda subsidiaries Takeda San Francisco, Millennium Pharmaceuticals and Takeda Bio Development Center; and CMC Center, a research centre dedicated to the design of synthetics and formulations and development of manufacturing processes required to provide new drug candidate substances.
‘We are delighted with the completion of the construction of the new facility that is set to assume a crucial role in the creation of antibody drugs that have potential to meet unmet needs,’ said Dr Tetsuo Miwa, general manager of the CMC Center.
‘By promoting the development of optimal antibody drugs and strengthening of CMC technical platforms based on our global network, we are determined to commit ourselves to bring superior new medicine to patients as promptly as possible.’
